Imeik Technology Development is a leading Chinese medical aesthetics company, best known for its portfolio of hyaluronic acid-based solutions and gel injectable products. Founded in 2004 and headquartered in Beijing, the company has built its reputation on product innovation and a differentiated strategy, enabling it to rank first in China with a market share by value exceeding 20% in 2024. In 2025, Imeik acquired a controlling stake (approximately 60%) in South Korea’s Regen Biotech through a joint venture with an investment fund. Presently, almost all of Imeik’s revenue is derived domestically in China.
2004
1.2K+
LTM Revenue $365M
LTM EBITDA $245M
$5.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of January 2026, Imeik Technology Development reported last 12-month revenue of $365M and EBITDA of $245M.
In the same period, Imeik Technology Development generated $340M in LTM gross profit and $214M in net income.
See Imeik Technology Development valuation multiples based on analyst estimatesIn the most recent fiscal year, Imeik Technology Development reported revenue of $437M and EBITDA of $336M.
Imeik Technology Development expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Imeik Technology Development valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $365M | XXX | $437M | XXX | XXX | XXX |
| Gross Profit | $340M | XXX | $414M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 95% | XXX | XXX | XXX |
| EBITDA | $245M | XXX | $336M | XXX | XXX | XXX |
| EBITDA Margin | 67% | XXX | 77% | XXX | XXX | XXX |
| EBIT | $243M | XXX | $312M | XXX | XXX | XXX |
| EBIT Margin | 67% | XXX | 71% | XXX | XXX | XXX |
| Net Profit | $214M | XXX | $283M | XXX | XXX | XXX |
| Net Margin | 59% | XXX | 65% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Imeik Technology Development has current market cap of CNY 43.9B (or $6.3B), and EV of CNY 40.8B (or $5.9B).
As of February 24, 2026, Imeik Technology Development's stock price is CNY 145 (or $21).
See Imeik Technology Development trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.9B | $6.3B | XXX | XXX | XXX | XXX | $0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialImeik Technology Development's trades at 16.2x EV/Revenue multiple, and 24.1x EV/EBITDA.
See valuation multiples for Imeik Technology Development and 15K+ public compsAs of February 24, 2026, Imeik Technology Development has market cap of $6.3B and EV of $5.9B.
Equity research analysts estimate Imeik Technology Development's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Imeik Technology Development has a P/E ratio of 29.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.3B | XXX | $6.3B | XXX | XXX | XXX |
| EV (current) | $5.9B | XXX | $5.9B | XXX | XXX | XXX |
| EV/Revenue | 16.2x | XXX | 16.2x | XXX | XXX | XXX |
| EV/EBITDA | 24.1x | XXX | 24.1x | XXX | XXX | XXX |
| EV/EBIT | 24.2x | XXX | 24.2x | XXX | XXX | XXX |
| EV/Gross Profit | 17.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.7x | XXX | 29.7x | XXX | XXX | XXX |
| EV/FCF | 29.7x | XXX | 29.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImeik Technology Development's last 12 month revenue growth is 14%
Imeik Technology Development's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Imeik Technology Development's rule of 40 is 91% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Imeik Technology Development's rule of X is 103% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Imeik Technology Development and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 67% | XXX | 67% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | -12% | XXX | XXX | XXX |
| Rule of 40 | 91% | XXX | 81% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 103% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Imeik Technology Development acquired XXX companies to date.
Last acquisition by Imeik Technology Development was XXXXXXXX, XXXXX XXXXX XXXXXX . Imeik Technology Development acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Imeik Technology Development founded? | Imeik Technology Development was founded in 2004. |
| Where is Imeik Technology Development headquartered? | Imeik Technology Development is headquartered in China. |
| How many employees does Imeik Technology Development have? | As of today, Imeik Technology Development has 1.2K+ employees. |
| Is Imeik Technology Development publicy listed? | Yes, Imeik Technology Development is a public company listed on SHE. |
| What is the stock symbol of Imeik Technology Development? | Imeik Technology Development trades under 300896 ticker. |
| When did Imeik Technology Development go public? | Imeik Technology Development went public in 2020. |
| Who are competitors of Imeik Technology Development? | Similar companies to Imeik Technology Development include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Imeik Technology Development? | Imeik Technology Development's current market cap is $6.3B |
| What is the current revenue of Imeik Technology Development? | Imeik Technology Development's last 12 months revenue is $365M. |
| What is the current revenue growth of Imeik Technology Development? | Imeik Technology Development revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Imeik Technology Development? | Current revenue multiple of Imeik Technology Development is 16.2x. |
| Is Imeik Technology Development profitable? | Yes, Imeik Technology Development is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Imeik Technology Development? | Imeik Technology Development's last 12 months EBITDA is $245M. |
| What is Imeik Technology Development's EBITDA margin? | Imeik Technology Development's last 12 months EBITDA margin is 67%. |
| What is the current EV/EBITDA multiple of Imeik Technology Development? | Current EBITDA multiple of Imeik Technology Development is 24.1x. |
| What is the current FCF of Imeik Technology Development? | Imeik Technology Development's last 12 months FCF is $199M. |
| What is Imeik Technology Development's FCF margin? | Imeik Technology Development's last 12 months FCF margin is 55%. |
| What is the current EV/FCF multiple of Imeik Technology Development? | Current FCF multiple of Imeik Technology Development is 29.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.